Pharmaceuticals
Patronus Biotech Receives Ethical Approval to Begin First-in-Human Phase 1 Trial of Three Multi-Stage Vaccines Against Malaria in Australia
Bellberry Limited Research Ethics Committee approves first-in-human study in Australia of Patronus Biotech's novel multi-stage virus-like-particle (VLP)-based malaria vaccine candidates targeting Plasmodium falciparum and Plasmodium vivax GUANGZHOU, China, Oct. 20, 2026 /PRNewswire/ -- Patronus ...
2026-10-20 20:40
1632
New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD
A Collaboration Leads to Molecularbiological Innovation MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAM...
2026-10-20 14:10
1037
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug candidate of Ascletis' once-weekly oral peptide p...
2026-10-20 08:10
3458
Frost & Sullivan awards WuXi AppTec with 2026 Global Company of the Year Recognition for CRDMO Leadership
Integrated capabilities, global capacity, and customer-centric innovation
strengthen WuXi AppTec's position in the evolving contract research,
development, and manufacturing (CRDMO) landscape.
SAN ANTONIO, Oct. 20, 2026 /PRNewswire/ -- Frost & Sullivan
2026-10-20 08:00
2230
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical co...
2026-10-19 19:16
1871
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
* Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). * Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including ...
2026-10-19 13:30
2181
HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES
SINGAPORE, Oct. 19, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the precl...
2026-10-19 11:00
3656
UEG Week 2026: Antibiotic use from childhood linked to higher odds of IBS in young adulthood
BARCELONA, Spain, Oct. 19, 2026 /PRNewswire/ -- Antibiotic use from childhood through early adulthood is associated with higher odds of irritable bowel syndrome (IBS) at age 24, with the odds increasing as the number of antibiotic prescriptions rose, according to a new study presented today atUEG...
2026-10-19 06:01
1696
Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies
ABU DHABI, UAE, Oct. 18, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has concluded its inaugural health and life sciences mission to China, advancing priority areas of collaboration designed to accelerate the translation ...
2026-10-18 01:54
5893
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
NEW TAIPEI CITY, Oct. 16, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a po...
2026-10-16 08:00
8058
Pope Leo XIV's Lung Cancer Diagnosis Puts Spotlight on Hope and Advances in Treatment
IASLC highlights global collaboration, advancing lung cancer care and bringing new hope to patients and families. DENVER, Oct. 15, 2026 /PRNewswire/ -- Pope Leo XIV's diagnosis of lung adenocarcinoma has brought global attention to a disease that affects millions of individuals and families acro...
2026-10-15 23:30
1902
Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform
Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent metabolic dysfunctions where complex disease biology and overlapping comorbidities will benefit from coordinated modulation of multiple therapeutic ta...
2026-10-15 19:30
1855
Opella: New study demonstrates successful cough treatment extends beyond symptom relief
PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic ...
2026-10-15 07:01
1873
Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Continuity ...
2026-10-14 20:00
1875
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in ...
2026-10-14 13:00
2809
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a pa...
2026-10-14 10:25
2374
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping th...
2026-10-14 04:20
2693
Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
* Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 * He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI...
2026-10-13 20:00
2828
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clini...
2026-10-13 19:23
2590
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ext...
2026-10-13 15:00
6494
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 275 media titles]
2026-10-23 21:52
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
26993
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
22645
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
21112
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
20567